In response to an FDA request for more data, Neoprobe said it will file a new-drug application for imaging agent Lymphoseek in the first quarter instead of this quarter. "We believe the earlier ... inclusion of the [safety] study data will support stronger product labeling as an outcome of a first-cycle review of the Lymphoseek NDA and may also positively impact market adoption," CEO David Bupp said.

Full Story:

Related Summaries